Intravenous Mepolizumab In Subjects With Hypereosinophilic Syndromes (HES)

PHASE3CompletedINTERVENTIONAL
Enrollment

86

Participants

Timeline

Start Date

March 23, 2004

Primary Completion Date

May 1, 2006

Study Completion Date

May 1, 2006

Conditions
HypereosinophiliaHypereosinophilic Syndrome
Interventions
DRUG

mepolizumab

Trial Locations (29)

2065

GSK Investigational Site, St Leonards

3000

GSK Investigational Site, Leuven

3010

GSK Investigational Site, Bern

3050

GSK Investigational Site, Melbourne

4101

GSK Investigational Site, South Brisbane

6005

GSK Investigational Site, West Perth

20892

GSK Investigational Site, Bethesda

24576

GSK Investigational Site, Bad Bramstedt

30625

GSK Investigational Site, Hanover

40138

GSK Investigational Site, Bologna

45229

GSK Investigational Site, Cincinnati

53792

GSK Investigational Site, Madison

55905

GSK Investigational Site, Rochester

59000

GSK Investigational Site, Lille

77030

GSK Investigational Site, Houston

80206

GSK Investigational Site, Denver

80802

GSK Investigational Site, Munich

84132

GSK Investigational Site, Salt Lake City

92103

GSK Investigational Site, San Diego

92150

GSK Investigational Site, Suresnes

02215

GSK Investigational Site, Boston

37203-1424

GSK Investigational Site, Nashville

23298-0568

GSK Investigational Site, Richmond

T6G 1Z2

GSK Investigational Site, Edmonton

R3C 0N2

GSK Investigational Site, Winnipeg

B3H 1V7

GSK Investigational Site, Halifax

L8N 3Z5

GSK Investigational Site, Hamilton

M5V 2T3

GSK Investigational Site, Toronto

H3A 1A1

GSK Investigational Site, Montreal

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY